CoChat
Sign Up
Cited by 366Antifungal resistance and susceptibilityFungal Infections and StudiesFungal and yeast genetics research

The DOI matches its Crossref record, with a small difference in title or year; 276 of the 276 references it cites were found in a registry or an index.

Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients

Maschmeyer, Georg, Haas, Antje, Cornely, Oliver A·2007·Drugs
DOI 10.2165/00003495-200767110-00004
Open this paper in CoChat — free account

Abstract

Morbidity and mortality caused by invasive Aspergillus infections are increasing. This is because of the higher number of patients with malignancies treated with intensive immunosuppressive therapy regimens as well as their improved survival from formerly fatal bacterial infections, and the rising number of patients undergoing allogeneic haematopoietic stem cell or organ transplantation. Early initiation of effective systemic antifungal treatment is essential for a successful clinical outcome in these patients; however, clinical clues for diagnosis are sparse and early microbiological proof of invasive aspergillosis (IA) is rare. Clinical diagnosis is based on pulmonary CT scan findings and non-culture based diagnostic techniques such as galactomannan or DNA detection in blood or bronchoalveolar lavage samples. Most promising outcomes can be expected in patients at high risk for aspergillosis in whom antifungal treatment has been started pre-emptively, backed up by laboratory and imaging findings. The gold standard of systemic antifungal treatment is voriconazole, which has been proven to be significantly superior to conventional amphotericin B and has led to a profound improvement of survival rates in patients with cerebral aspergillosis. Liposomal amphotericin B at standard dosages appears to be a suitable alternative for primary treatment, while caspofungin, amphotericin B lipid complex or posaconazole have shown partial or complete response in patients who had been refractory to or intolerant of primary antifungal therapy. Combination therapy with two antifungal compounds may be a promising future strategy for first-line treatment. Lung resection helps to prevent fatal haemorrhage in single patients with pulmonary lesions located in close proximity to larger blood vessels, but is primarily considered for reducing the risk of relapse during subsequent periods of severe immunosuppression. Strict reverse isolation appears to reduce the incidence of aspergillosis in allogeneic stem cell transplant recipients and patients with acute myeloid leukaemia undergoing aggressive anticancer therapy. Well designed, prospective randomised studies on infection control measures effective to prevent aspergillosis are lacking. Prophylactic systemic antifungal treatment with posaconazole significantly improves survival and reduces IA in acute myeloid leukaemia patients and reduces aspergillosis incidence rates in patients with intermediate-to-severe graft-versus-host reaction emerging after allogeneic haematopoietic stem cell transplantation. Voriconazole prophylaxis may be suitable for prevention of IA as well; however, the results of large clinical trials are still awaited.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200767110-00004

Cites

276 of 276 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–276 of 276

Research works printed but not linked: 6

  1. Chamilos, 2006, Haematologica, 91, 986
  2. Michailov, 1996, Bone Marrow Transplant, 17, 569
  3. Martino, 1997, Haematologica, 82, 297
  4. Goodley, 1994, JHosp Infect, 26, 27
  5. Bohme, 2000, Onkologie, 23, 145
  6. Lopez-Medrano, 2005, Rev Esp Quimioter, 18, 14

Cited by

Sorted by citations

See all 366

Related

See all

Metadata

Authors
Maschmeyer, G., Haas, A., & Cornely, O. A.
Affiliations
  • Klinikum Ernst von Bergmann (DE)
  • University Hospital Cologne (DE)
Corresponding author
Maschmeyer, Georg
ORCID
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2007
Volume
67
Issue
11
Pages
1567-1601
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-200767110-00004
OpenAlex
W2088013043
Cited by
366
References
276
Citations by year
2026: 4 · 2025: 7 · 2024: 13 · 2023: 9 · 2022: 8 · 2021: 16 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 12 · 2016: 21 · 2015: 23 · 2014: 27 · 2013: 24 · 2012: 30
FWCI
4.01
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
invasive aspergillosis, Aspergillus, voriconazole, amphotericin B, caspofungin, posaconazole, antifungal prophylaxis, immunosuppression, hematopoietic stem cell transplantation, acute myeloid leukemia, galactomannan, cerebral aspergillosis, lung resection, infection control, graft-versus-host disease
MeSH terms
Antifungal Agents, Antineoplastic Agents, Aspergillosis, Drug Therapy, Combination, Humans, Neoplasms, Quarantine, Risk Factors, Transplantation Immunology, Organ Transplantation, Immunocompromised Host, Hematopoietic Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review